Market Place
Sourcing Support
All News #Library
Biotech
Lyra Ditches Sole Rhinosinusitis Asset, Lays Off All Employees
13 Jan 2026 //
FIERCE BIOTECH
Lyra Therapeutics Reports Q3 2025 Financials & Corporate Update
12 Nov 2025 //
GLOBENEWSWIRE
Lyra Pharma Reveals LYR-210 Clinical Strategy & ENLIGHTEN 2 Study
06 Oct 2025 //
GLOBENEWSWIRE
Lyra Therapeutics Announces Q2 2025 Financial Results & Update
12 Aug 2025 //
GLOBENEWSWIRE
Lyra’s Stock Soar on Phase 3 Success for Rhinosinusitis Treatment
05 Jun 2025 //
ENDPTS
Lyra Reports Positive Ph3 ENLIGHTEN 2 Data In CRS Patients
02 Jun 2025 //
GLOBENEWSWIRE
Lyra to Present 52-Week ENLIGHTEN 1 Data for Chronic Sinusitis
07 May 2025 //
GLOBENEWSWIRE
Lyra Therapeutics Reports Q1 2025 Financial Results and Update
06 May 2025 //
GLOBENEWSWIRE
Lyra Therapeutics Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Lyra Therapeutics Fully Enrolls Phase 3 Trial Of LYR-210
15 Oct 2024 //
GLOBENEWSWIRE
Lyra Therapeutics To Present LYR-210 And LYR-220 Study Results
27 Sep 2024 //
GLOBENEWSWIRE
Lyra Therapeutics Reports Q2 2024 Financial Results And Corporate Update
14 Aug 2024 //
GLOBENEWSWIRE
Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference
13 Jul 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.